India Pharma Conference 2026 to spotlight innovation, global partnerships in New Delhi

Discussions are likely to centre on how the country can move up the pharmaceutical value chain

Aurobindo Pharma’s CuraTeQ achieves Phase 3 success for Omalizumab biosimilar

The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline

Biocon renames Irish step-down subsidiary as Biocon Biologics Ireland

Move aligns global biologics identity under the Biocon Biologics brand

PHARMEXCIL Chintan Shivir in Hyderabad charts roadmap to scale India’s pharma exports

Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26

Teva hits major biosimilar milestones with FDA nod and regulatory filings

The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia

Shreehas Tambe appointed CEO & Managing Director of Biocon

Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited

CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG

STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories

Lupin’s Vinita Gupta honoured as CNBC Changemaker for revolutionising U.S. healthcare access

Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy

Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment

ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar

STADA & Bio-Thera bag European nod for Gotenfia